Publications

Found 599 results
Type [ Year(Desc)]
2021
T Wu, HX Nguyen, and N Bursac. In vitro discovery of novel prokaryotic ion channel candidates for antiarrhythmic gene therapy.. Vol. 654., 2021.
R-Z Zhan, L Rao, Z Chen, N Strash, and N Bursac. "Loss of sarcomeric proteins via upregulation of JAK/STAT signaling underlies interferon-γ-induced contractile deficit in engineered human myocardium." Acta Biomaterialia 126 (2021): 144-153.
Z Fralish, EM Lotz, T Chavez, A Khodabukus, and N Bursac. "Neuromuscular Development and Disease: Learning From in vitro and in vivo Models." Frontiers in Cell and Developmental Biology 9 (2021).
K Saha, EJ Sontheimer, PJ Brooks, MR Dwinell, CA Gersbach, DR Liu, SA Murray, SQ Tsai, RC Wilson, DG Anderson et al. "The NIH Somatic Cell Genome Editing program." Nature 592, no. 7853 (2021): 195-204.
B Arnson, J Wang, D Courtney, S-O Han, S Li, BR Cullen, N Bursac, and D Koeberl. "Single Vector AAV Approach to Genome Editing in Pompe Disease." In Molecular Therapy, 291. Vol. 29. 2021.
J Wang, CJ Zhou, A Khodabukus, S Tran, S-O Han, AL Carlson, L Madden, PS Kishnani, DD Koeberl, and N Bursac. "Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease." Communications Biology 4, no. 1 (2021).
2022
N Strash, S DeLuca, Janer G Carattini, Y Chen, J Scherba, M Jain, R Naseri, T Wu, and N Bursac. "BRAF-V600E-Mediated Erk Activation Promotes Sustained Cell Cycling and Broad Transcriptional Changes in Neonatal Cardiomyocytes." (2022).
JC Scherba, MK Halushka, ND Andersen, JJ Maleszewski, AP Landstrom, N Bursac, and C Glass. "BRG1 is a biomarker of hypertrophic cardiomyopathy in human heart specimens." Scientific Reports 12, no. 1 (2022).
S DeLuca, and N Bursac. "CRISPR Library Screening in Cultured Cardiomyocytes." Methods in Molecular Biology (Clifton, N.J.) 2485 (2022): 1-13.
CG Vann, X Zhang, A Khodabukus, MC Orenduff, Y-H Chen, DL Corcoran, GA Truskey, N Bursac, and VB Kraus. "Differential microRNA profiles of intramuscular and secreted extracellular vesicles in human tissue-engineered muscle." Frontiers in Physiology 13 (2022).
HX Nguyen, T Wu, D Needs, H Zhang, RM Perelli, S DeLuca, R Yang, M Pan, AP Landstrom, C Henriquez et al. "Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy." Nature Communications 13, no. 1 (2022).
V Janbandhu, V Tallapragada, R Patrick, Y Li, D Abeygunawardena, DT Humphreys, EMMA Martin, AO Ward, O Contreras, N Farbehi et al. "Hif-1a suppresses ROS-induced proliferation of cardiac fibroblasts following myocardial infarction." Cell Stem Cell 29, no. 2 (2022): 281-297.e12.
DE Lee, LK McKay, A Bareja, Y Li, A Khodabukus, N Bursac, GA Taylor, GS Baht, and JP White. "Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro/adipogenic progenitor signaling." Nature Communications 13, no. 1 (2022).
J Wang, T Broer, T Chavez, CJ Zhou, S Tran, Y Xiang, A Khodabukus, Y Diao, and N Bursac. "Myoblast deactivation within engineered human skeletal muscle creates a transcriptionally heterogeneous population of quiescent satellite-like cells." Biomaterials 284 (2022): 121508.
AM Vekstein, DC Wendell, S DeLuca, R Yan, Y Chen, M Bishawi, GW Devlin, A Asokan, KD Poss, DE Bowles et al. "Targeted Delivery for Cardiac Regeneration: Comparison of Intra-coronary Infusion and Intra-myocardial Injection in Porcine Hearts." Frontiers in Cardiovascular Medicine 9 (2022).
JC Scherba, R Karra, JW Turek, and N Bursac. "Toward improved understanding of cardiac development and congenital heart disease: The advent of cardiac organoids." The Journal of Thoracic and Cardiovascular Surgery 164, no. 6 (2022): 2013-2018.
A Khodabukus, T Guyer, AC Moore, MM Stevens, RE Guldberg, and N Bursac. "Translating musculoskeletal bioengineering into tissue regeneration therapies." Science Translational Medicine 14, no. 666 (2022).
2023
HX Nguyen, T Wu, D Needs, H Zhang, RM Perelli, S DeLuca, R Yang, M Pan, AP Landstrom, C Henriquez et al. "Author Correction: Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy." Nature Communications 14, no. 1 (2023).
A Chakraborty, NG Peterson, JS King, RT Gross, MM Pla, A Thennavan, KC Zhou, S DeLuca, N Bursac, DE Bowles et al. "Conserved chamber-specific polyploidy maintains heart function in Drosophila." Development 150, no. 16 (2023).
Q Zhang, R-Z Zhan, M Patsy, B Li, Y Chen, BD Lipes, N Bursac, and GA Truskey. "Differential Response of Engineered Human Cardiac Tissues to Delta and Omicron COVID-19 Virus." Journal of the American Heart Association 12, no. 12 (2023).
R Yan, V Cigliola, KA Oonk, Z Petrover, S DeLuca, DW Wolfson, A Vekstein, MA Mendiola, G Devlin, M Bishawi et al. "An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair." Cell Stem Cell 30, no. 1 (2023): 96-111.e6.
MA Fuchs, EJ Burke, N Latic, S Murray, H Li, M Sparks, D Abraham, H Zhang, P Rosenberg, S Hänzelmann et al. "Fibroblast Growth Factor (FGF) 23 and FGF Receptor 4 promote cardiac metabolic remodeling in chronic kidney disease." Res Sq (2023).
D Needs, T Wu, HX Nguyen, CS Henriquez, and N Bursac. "Prokaryotic voltage-gated sodium channels are more effective than endogenous Nav1.5 channels in rescuing cardiac action potential conduction: an in silico study." American Journal of Physiology Heart and Circulatory Physiology 325, no. 5 (2023): H1178-H1192.
2024
N Strash, S DeLuca, GL Janer Carattini, Y Chen, T Wu, A Helfer, J Scherba, I Wang, M Jain, R Naseri et al. "Time-dependent effects of BRAF-V600E on cell cycling, metabolism, and function in engineered myocardium." Science Advances 10, no. 4 (2024).

Pages